Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy

Eduard Dolusic, Pierre Larrieu, Sébastien Blanc, Laurence Moineaux, Delphine Colette, Graeme Fraser, Vincent Stroobant, Luc Pilotte, Didier Colaux, Johan Wouters, Bernard Masereel, Benoît Van den Eynde, Raphaël Frédérick

Research output: Contribution to conferencePoster

Abstract

Immunotherapy is a promising novel and validated strategy for cancer therapy. It consists of the therapeutic vaccination of patients to stimulate their (natural) immune system against cancer cells. However, this approach showed a limited efficacy in vivo because cancer cells develop enzymatic mechanisms allowing tumours to resist or escape immune rejection. Among the enzymes involved, indoleamine 2,3-dioxygenase (IDO) was identified as a potential actor. IDO catalyses the rapid degradation of tryptophan (Trp) into N-formylkynurenine. This results in a local Trp depletion that severely affects T-cells proliferation and is thereby deeply immunosuppressive. Recently, the team of Prof. Van den Eynde demonstrated that many human tumours express IDO in a constitutive manner and that this expression allows cancer cells to escape immune rejection. IDO was thus clearly identified as an attractive target for the development of inhibitors. The recent elucidation of the three-dimensional structures of IDO, in complex with phenylimidazole and the cyanide ion (CN¯), provide important results for the structure-based drug discovery and design of novel IDO inhibitors. In the present work, we applied virtual screening for the discovery of new IDO inhibitors. As a result, five novel scaffolds with inhibitory potencies in the micromolar range were identified. Among these, the most promising candidate (1: IC50 = 65 µM) was selected and its inhibitory potency improved by chemical modifications. This led to a 7-fold improvement of the inhibitory potency of the hit selected. In this communication, the identification of 1, the synthesis and biological evaluation of a series of analogues as well as a modeling study explaining the SAR's will be presented.
Original languageEnglish
PagesBook of Abstracts, 25èmes Journées Franco-belges de Pharmacochimie, 19-20/05/11, Liège, P37, p. 62
Number of pages1
Publication statusPublished - 2011
EventJFB 2011. - Liege, Belgium
Duration: 19 May 2011 → …

Conference

ConferenceJFB 2011.
CountryBelgium
CityLiege
Period19/05/11 → …

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Immunotherapy
Neoplasms
Tryptophan
Drug Design
Cyanides
Drug Discovery
Immunosuppressive Agents
indole
Inhibitory Concentration 50
Immune System
Vaccination
Cell Proliferation
Ions
T-Lymphocytes
Enzymes
Therapeutics

Cite this

Dolusic, E., Larrieu, P., Blanc, S., Moineaux, L., Colette, D., Fraser, G., ... Frédérick, R. (2011). Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy. Book of Abstracts, 25èmes Journées Franco-belges de Pharmacochimie, 19-20/05/11, Liège, P37, p. 62. Poster session presented at JFB 2011., Liege, Belgium.
Dolusic, Eduard ; Larrieu, Pierre ; Blanc, Sébastien ; Moineaux, Laurence ; Colette, Delphine ; Fraser, Graeme ; Stroobant, Vincent ; Pilotte, Luc ; Colaux, Didier ; Wouters, Johan ; Masereel, Bernard ; Van den Eynde, Benoît ; Frédérick, Raphaël. / Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy. Poster session presented at JFB 2011., Liege, Belgium.1 p.
@conference{cc1d7e2afbb14a18a0c15ae5106190d1,
title = "Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy",
abstract = "Immunotherapy is a promising novel and validated strategy for cancer therapy. It consists of the therapeutic vaccination of patients to stimulate their (natural) immune system against cancer cells. However, this approach showed a limited efficacy in vivo because cancer cells develop enzymatic mechanisms allowing tumours to resist or escape immune rejection. Among the enzymes involved, indoleamine 2,3-dioxygenase (IDO) was identified as a potential actor. IDO catalyses the rapid degradation of tryptophan (Trp) into N-formylkynurenine. This results in a local Trp depletion that severely affects T-cells proliferation and is thereby deeply immunosuppressive. Recently, the team of Prof. Van den Eynde demonstrated that many human tumours express IDO in a constitutive manner and that this expression allows cancer cells to escape immune rejection. IDO was thus clearly identified as an attractive target for the development of inhibitors. The recent elucidation of the three-dimensional structures of IDO, in complex with phenylimidazole and the cyanide ion (CN¯), provide important results for the structure-based drug discovery and design of novel IDO inhibitors. In the present work, we applied virtual screening for the discovery of new IDO inhibitors. As a result, five novel scaffolds with inhibitory potencies in the micromolar range were identified. Among these, the most promising candidate (1: IC50 = 65 µM) was selected and its inhibitory potency improved by chemical modifications. This led to a 7-fold improvement of the inhibitory potency of the hit selected. In this communication, the identification of 1, the synthesis and biological evaluation of a series of analogues as well as a modeling study explaining the SAR's will be presented.",
author = "Eduard Dolusic and Pierre Larrieu and S{\'e}bastien Blanc and Laurence Moineaux and Delphine Colette and Graeme Fraser and Vincent Stroobant and Luc Pilotte and Didier Colaux and Johan Wouters and Bernard Masereel and {Van den Eynde}, Beno{\^i}t and Rapha{\"e}l Fr{\'e}d{\'e}rick",
year = "2011",
language = "English",
pages = "Book of Abstracts, 25{\`e}mes Journ{\'e}es Franco--belges de Pharmacochimie, 19--20/05/11, Li{\`e}ge, P37, p. 62",
note = "JFB 2011. ; Conference date: 19-05-2011",

}

Dolusic, E, Larrieu, P, Blanc, S, Moineaux, L, Colette, D, Fraser, G, Stroobant, V, Pilotte, L, Colaux, D, Wouters, J, Masereel, B, Van den Eynde, B & Frédérick, R 2011, 'Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy', JFB 2011., Liege, Belgium, 19/05/11 pp. Book of Abstracts, 25èmes Journées Franco-belges de Pharmacochimie, 19-20/05/11, Liège, P37, p. 62.

Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy. / Dolusic, Eduard; Larrieu, Pierre; Blanc, Sébastien; Moineaux, Laurence; Colette, Delphine; Fraser, Graeme; Stroobant, Vincent; Pilotte, Luc; Colaux, Didier; Wouters, Johan; Masereel, Bernard; Van den Eynde, Benoît; Frédérick, Raphaël.

2011. Book of Abstracts, 25èmes Journées Franco-belges de Pharmacochimie, 19-20/05/11, Liège, P37, p. 62 Poster session presented at JFB 2011., Liege, Belgium.

Research output: Contribution to conferencePoster

TY - CONF

T1 - Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy

AU - Dolusic, Eduard

AU - Larrieu, Pierre

AU - Blanc, Sébastien

AU - Moineaux, Laurence

AU - Colette, Delphine

AU - Fraser, Graeme

AU - Stroobant, Vincent

AU - Pilotte, Luc

AU - Colaux, Didier

AU - Wouters, Johan

AU - Masereel, Bernard

AU - Van den Eynde, Benoît

AU - Frédérick, Raphaël

PY - 2011

Y1 - 2011

N2 - Immunotherapy is a promising novel and validated strategy for cancer therapy. It consists of the therapeutic vaccination of patients to stimulate their (natural) immune system against cancer cells. However, this approach showed a limited efficacy in vivo because cancer cells develop enzymatic mechanisms allowing tumours to resist or escape immune rejection. Among the enzymes involved, indoleamine 2,3-dioxygenase (IDO) was identified as a potential actor. IDO catalyses the rapid degradation of tryptophan (Trp) into N-formylkynurenine. This results in a local Trp depletion that severely affects T-cells proliferation and is thereby deeply immunosuppressive. Recently, the team of Prof. Van den Eynde demonstrated that many human tumours express IDO in a constitutive manner and that this expression allows cancer cells to escape immune rejection. IDO was thus clearly identified as an attractive target for the development of inhibitors. The recent elucidation of the three-dimensional structures of IDO, in complex with phenylimidazole and the cyanide ion (CN¯), provide important results for the structure-based drug discovery and design of novel IDO inhibitors. In the present work, we applied virtual screening for the discovery of new IDO inhibitors. As a result, five novel scaffolds with inhibitory potencies in the micromolar range were identified. Among these, the most promising candidate (1: IC50 = 65 µM) was selected and its inhibitory potency improved by chemical modifications. This led to a 7-fold improvement of the inhibitory potency of the hit selected. In this communication, the identification of 1, the synthesis and biological evaluation of a series of analogues as well as a modeling study explaining the SAR's will be presented.

AB - Immunotherapy is a promising novel and validated strategy for cancer therapy. It consists of the therapeutic vaccination of patients to stimulate their (natural) immune system against cancer cells. However, this approach showed a limited efficacy in vivo because cancer cells develop enzymatic mechanisms allowing tumours to resist or escape immune rejection. Among the enzymes involved, indoleamine 2,3-dioxygenase (IDO) was identified as a potential actor. IDO catalyses the rapid degradation of tryptophan (Trp) into N-formylkynurenine. This results in a local Trp depletion that severely affects T-cells proliferation and is thereby deeply immunosuppressive. Recently, the team of Prof. Van den Eynde demonstrated that many human tumours express IDO in a constitutive manner and that this expression allows cancer cells to escape immune rejection. IDO was thus clearly identified as an attractive target for the development of inhibitors. The recent elucidation of the three-dimensional structures of IDO, in complex with phenylimidazole and the cyanide ion (CN¯), provide important results for the structure-based drug discovery and design of novel IDO inhibitors. In the present work, we applied virtual screening for the discovery of new IDO inhibitors. As a result, five novel scaffolds with inhibitory potencies in the micromolar range were identified. Among these, the most promising candidate (1: IC50 = 65 µM) was selected and its inhibitory potency improved by chemical modifications. This led to a 7-fold improvement of the inhibitory potency of the hit selected. In this communication, the identification of 1, the synthesis and biological evaluation of a series of analogues as well as a modeling study explaining the SAR's will be presented.

M3 - Poster

SP - Book of Abstracts, 25èmes Journées Franco-belges de Pharmacochimie, 19-20/05/11, Liège, P37, p. 62

ER -

Dolusic E, Larrieu P, Blanc S, Moineaux L, Colette D, Fraser G et al. Indole-pyridinyl-ethanones as novel inhibitors of indoleamine-2,3-dioxygenase (IDO), a promising target for anti-cancer immunotherapy. 2011. Poster session presented at JFB 2011., Liege, Belgium.